Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | PRCP | P42785 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25627922 | 0.86 | CHRM5 (0.44) | GID4CHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL25627952 | 0.84 | MEN1 (0.45) | GID4CHRNB2CHRNA4SMN1; SMN2PRCP | |
| SCHEMBL25627881 | 0.82 | GID4 (0.42) | GID4CHRNB2CHRNA4CYP3A4ALOX15 | |
| SCHEMBL4522448 | 0.76 | GID4 (0.39) | GID4CYP3A4ALOX15CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL4684123 | 0.75 | GID4 (0.38) | GID4HTR2CGAA | |
| SCHEMBL22430796 | 0.74 | CHRNB2 (0.38) | CHRNB2CHRNA4HTR2CPRCPGAA | |
| SCHEMBL21523791 | 0.74 | KDM1A (0.45) | CHRNB2CHRNA4HTR2CPRCPKDM4E | |
| SCHEMBL22423680 | 0.74 | HTR2C (0.57) | CHRNB2CHRNA4HTR2CPRCPALDH1A1 | |
| SCHEMBL29585972 | 0.74 | KDM1A (0.45) | CHRNB2CHRNA4HTR2CPRCPKDM4E | |
| SCHEMBL30092890 | 0.74 | HTR2C (0.61) | CHRNB2CHRNA4HTR2CGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | GID4 4555/4885CHRNB2 163/4885CHRNA4 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.